CN Mobile Logo


Chronic Myeloid Leukemia

Chronic Myeloid Leukemia

A 5-year analysis of the DASISION trial showed that dasatinib continued to offer better responses than imatinib in patients with chronic myeloid leukemia.

Chronic myeloid leukemia patients had a significantly increased prevalence of prior malignancies and autoimmune disorders compared with the general population.

The addition of pegylated interferon-ɑ2b to dasatinib yielded promising results in a small trial of newly diagnosed chronic myeloid leukemia patients.

The efficacy of ponatinib in patients with newly diagnosed CML compared with imatinib remains to be established, as a randomized phase III trial was terminated early due to concerns regarding arterial occlusive events with ponatinib.

A rapid reduction in BCR-ABL transcript levels and the halving time of those levels are predictive of better outcomes in patients with chronic myeloid leukemia.

Patients with CML who are treated with dasatinib commonly experience lymphocytosis, and the condition is associated with higher response rates and increased survival in patients who are refractory or intolerant of imatinib.

Elevated levels of TGF-α and IL-6 in newly diagnosed chronic-phase chronic myeloid leukemia patients were predictive of failure to achieve molecular response.


Subscribe to Chronic Myeloid Leukemia on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.